Name: Modeling human fatty liver disease in vitro
Uploaded: 2022-05-23T00:00:00.0000000
Duration: T00H02M14S
Description: Modeling human fatty liver disease in vitro

Name: Modeling human fatty liver disease in vitro

Description: Modeling human fatty liver disease in vitro

Thumbnail URL: https://cadmoremediastorage.blob.core.windows.net/5efbc322-82fe-4f82-a0ea-2187329a12c0/videoscrubberimages/Scrubber_1.jpg

Duration: T00H02M14S

Embed URL: https://stream.cadmore.media/player/5efbc322-82fe-4f82-a0ea-2187329a12c0

Content URL: https://cadmoreoriginalmedia.blob.core.windows.net/5efbc322-82fe-4f82-a0ea-2187329a12c0/BTN In Focus - Modelling Disease - V4.mp4?sv=2019-02-02&sr=c&sig=WygK%2F1vg%2Fx9kQsmp4%2BNqOOnpHqtO8kb%2FpPFUzdTnt40%3D&st=2024-11-05T03%3A46%3A25Z&se=2024-11-05T05%3A51%3A25Z&sp=r

Upload Date: 2022-05-23T00:00:00.0000000

Transcript: Language: EN.
Segment:0 .
[MUSIC PLAYING]
ANNIE COULSON: Non-alcoholic fatty liver disease or NAFLD is a spectrum of metabolic diseases linked to obesity and diabetes. An estimated 25% of our global population have NAFLD, and around 20% of people with NAFLD go on to develop non-alcoholic steatohepatitis or NASH. Left untreated, NASH can cause cirrhosis and/or liver cancer. NASH is poised to become a huge economic burden. Despite widespread R&D effort, no regulatory approved drug treatments are available because traditional preclinical models failed to predict the efficacy of potential drugs in humans, and often the only viable treatment is liver transplant.
ANNIE COULSON: Organ-on-a-chip models, also termed OOC models, enable us to recreate human physiology and disease in the lab by culturing cells in a perfused 3D environment. Experts suggest that incorporating OOC models into drug discovery workflows will increase success by predicting outcomes that other models cannot, saving costs and helping to bring treatments to patients more rapidly. NASH OOC models can be used to test the efficacy and toxicity of a variety of potential anti-NASH therapeutics via detection of clinically translatable biomarkers over time and exploration of disease relevant liver tissues.
ANNIE COULSON: Getting started with Organ-on-a-chip is easy. CN Bio's NASH-in-a-box used in combination with the PhysioMimix OOC provides everything required to recreate healthy and diseased liver physiology in the lab. NASH-in-a-box provides a rapid, usable, cost-effective alternative for deriving human relevant data to facilitate more informed decisions about which medicines to take to the clinic. In this In Focus sponsored by CN Bio, we will explore preclinical models of fatty liver disease with a special focus on Organ-on-a-chip technologies.
ANNIE COULSON: You can keep up to date with In Focus at www.BioTechniques.com, and follow us on Facebook, Twitter and LinkedIn for all the updates. [MUSIC PLAYING]

Cadmore media player playing video Modeling human fatty liver disease in vitro

Video Player

Transcript

Segments

End of Video Player Control